Results 81 to 90 of about 5,257 (166)

Tolvaptan for treatment of iatrogenic hyponatremia [PDF]

open access: yesJournal of Neuroanaesthesiology and Critical Care, 2016
openaire   +3 more sources

The Role of Baseline Total Kidney Volume Growth Rate in Predicting Tolvaptan Efficacy for ADPKD Patients: A Feasibility Study. [PDF]

open access: yesJ Clin Med
Dev H   +12 more
europepmc   +1 more source

MP340LONG-TERM RENOPROTECTIVE EFFECTS OF TOLVAPTAN IN PATIENTS WITH ACUTE HEART FAILURE [PDF]

open access: bronze, 2017
Tatsufumi Oka   +7 more
openalex   +1 more source

Five years of post-marketing liver safety data from the tolvaptan Risk Evaluation and Mitigation Strategy. [PDF]

open access: yesClin Kidney J
Lohrmann E   +12 more
europepmc   +1 more source

Tolvaptan for the Treatment of Elephantiasis Nostras Verrucosa

open access: yesInternal Medicine, 2019
Yuko Eda   +3 more
openaire   +4 more sources

Commentary: Tolvaptan for Autosomal Dominant Polycystic Kidney Disease (ADPKD) - an update. [PDF]

open access: yesBMC Nephrol
Gittus M   +12 more
europepmc   +1 more source

Altered Hepatobiliary Disposition of Tolvaptan and Selected Tolvaptan Metabolites in a Rodent Model of Polycystic Kidney Disease [PDF]

open access: bronze, 2018
James J. Beaudoin   +6 more
openalex   +1 more source

The prospect of novel orphan therapeutic protocol for TSC2/PKD1 contiguous gene syndrome: a case report. [PDF]

open access: yesBMC Nephrol
Agavriloaei BD   +6 more
europepmc   +1 more source

Urine Osmolality, Response to Tolvaptan, and Outcome in Autosomal Dominant Polycystic Kidney Disease: Results from the TEMPO 3:4 Trial

open access: bronze, 2016
Olivier Devuyst   +9 more
openalex   +1 more source

Home - About - Disclaimer - Privacy